Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: Eric Pottier

TxCell – antigen-specific Type 1 Treg cells

Posted on by

TxCell is a biotech company developing innovative and personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for autoimmune diseases and severe chronic inflammatory diseases.

TxCell – antigen-specific Type 1 Treg cells

txcell Continue reading →

Posted in Biotech Companies, Biotech Companies France | Tagged Ag-Treg, Ag-Tregs, antigen specific regulatory T-cell, antigen specific regulatory T-cells, antigen-specific Type 1 Treg cell, antigen-specific Type 1 Treg cells, Arnaud Foussat, arthritis, Auriga Partners, autoimmune, autoimmune diseases, autoimmune uveitis, AXA Private Equity, Bernard Daugeras, Bpifrance, Bpifrance Innobio, chronic inflammatory, chronic inflammatory disease, Col-Treg, colitis, Crohn, Crohn’s disease, Damian Marron, Emmanuel Fiessinger, Eric Pottier, François Meyer, immune modulatory, immuno-modulatory, Innobio, Innovation Capital, INSERM, Institut National de la Santé et de la Recherche Médicale, Laurent Arthaud, Laurent Higueret, Marie Landel, Marie-Laure Garrigues, Miguel Forte, multiple sclerosis, Ovasaves, phase IIb placebo controlled study, Raphael Flipo, Seventure Partners, severe chronic inflammatory diseases, T cell immunotherapies, T cell immunotherapy, TxCell, TxCell - antigen-specific Type 1 Treg cells, Type 1 Treg cell, Type 1 Treg cells, uveitis

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress